INmune Bio Inc. Announces Expansion Of Phase II Clinical Trial For Alzheimer's Disease In Europe; The Company Received A Cash Refund Of ~$2.8M Pursuant To An Australian Research And Development Tax Incentive
Portfolio Pulse from Benzinga Newsdesk
INmune Bio Inc. (NASDAQ:INMB) has expanded its Phase II clinical trial for Alzheimer's Disease to Europe and received a $2.8M cash refund from an Australian R&D tax incentive. The trial, which is already enrolling patients in Australia, Canada, and the UK, has shown promising results in a prior Phase I trial with decreases in neuroinflammation and improvements in brain structure. The EU expansion is part of a strategy to prepare for a global Phase III trial. The Australian tax refund will be reinvested into the company's clinical programs.
November 15, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio Inc. is advancing its Phase II clinical trial for Alzheimer's in Europe and has received a $2.8M cash refund from Australia. The trial's prior success and the non-dilutive funding are positive indicators for the company's future prospects.
The expansion of INmune Bio's clinical trial into Europe and the receipt of a substantial R&D tax refund are significant developments that could positively impact investor sentiment. The successful Phase I trial results and the strategy to prepare for a global Phase III trial may increase confidence in the company's growth potential and its product, XPro™. The non-dilutive nature of the funding is also a positive factor, as it does not dilute existing shareholders' equity.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100